BIO Finance Trends: Drug Developers Face Harsh Realities As Funding Constraints Continue

Dealmaking Has Become A Cash Alternative

 
• By Mandy Jackson
  
Declining biotech valuations are not expected to reverse course soon (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from BIO

More from Conferences